ライフサイエンスコーパス: enzyme inhibitor

1 nt with enalapril, an angiotensin converting enzyme inhibitor.

2 (AmBF3) to generate monovalent or trivalent enzyme inhibitors.

3 compounds function as reversible competitive enzyme inhibitors.

4 ation in the construction of mechanism-based enzyme inhibitors.

5 uretics, digoxin, and angiotensin converting enzyme inhibitors.

6 s a powerful approach for the development of enzyme inhibitors.

7 and acyclonucleoside analogues as potential enzyme inhibitors.

8 receptor blockers and angiotensin-converting enzyme inhibitors.

9 e for the high-throughput discovery of novel enzyme inhibitors.

10 the intracellular mechanisms of action of E1 enzyme inhibitors.

11 xIN(Bt)) that ToxI RNAs are highly selective enzyme inhibitors.

12 d be feasible to design and test as specific enzyme inhibitors.

13 ticosteroid resistant but suppressed by PI3K enzyme inhibitors.

14 use of the biosensor as a screening tool for enzyme inhibitors.

15 te, offering opportunities for new lectin or enzyme inhibitors.

16 to identify and measure the effectiveness of enzyme inhibitors.

17 placement therapy, or angiotensin-converting enzyme inhibitors.

18 icipants using ACE (angiotensin I-converting enzyme) inhibitors.

19 However, under harsh conditions (enzyme:inhibitor = 1:2000), OXA-24 was inhibited via dec

20 In OXA-24, under mild conditions (enzyme:inhibitor = 1:4), only hydrolyzed products were d

21 g azathioprine and an angiotensin-converting enzyme inhibitor, 171 (12.9%) were taking a sulfonylurea

22 zathiamin, a noncleavable thiamin analog and enzyme inhibitor (2.7 A; R, 0.233; Rfree, 0.267).

23 nts were treated with angiotensin-converting enzyme inhibitors, 34% (95% CI: 28%-41%) with beta-block

24 imaged the effects of angiotensin-converting enzyme inhibitor (5 mg/kg enalapril).

25 valuate the impact of angiotensin-converting enzyme inhibitors (ACE-i) on the cardiovascular outcome

26 assess the effects of angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin receptor bloc

27 of the casein-derived angiotensin converting enzyme-inhibitor (ACE-I) peptides VPP, IPP, RYLGY, RYLG,

28 no consensus whether angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker

29 ptor blocker (ARB) or angiotensin-converting enzyme inhibitor (ACEI) has demonstrated particular prom

30 all of whom received angiotensin-converting enzyme inhibitor (ACEI) therapy at the end of the trial

31 ness ratios (ICER) of angiotensin-converting enzyme inhibitor (ACEI), beta-blocker (BB), and aldoster

32 e association between angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (AR

33 hat is, high doses of angiotensin-converting enzyme inhibitor (ACEi, or angiotensin receptor blocker)

34 e association between angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blocke

35 Angiotensin-converting enzyme inhibitors (ACEi) for renin-angiotensin-aldostero

36 d therapy with either angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blocker

37 Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blocker

38 Although statins, angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blocker

39 We focused on angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers

40 n fraction, including angiotensin-converting enzyme inhibitors (ACEI), angiotensin receptor blockers

41 lockers, statins, and angiotensin-converting enzyme inhibitors (ACEI)/angiotensin II receptor blocker

42 m excretion caused by angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor block

43 the pattern of use of angiotensin-converting enzyme inhibitors (ACEIs) in coronary artery bypass graf

44 Angiotensin-converting enzyme inhibitors (ACEIs) may retard the development of

45 Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blocke

46 Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blocke

47 ave shown that use of angiotensin-converting enzyme inhibitors (ACEIs) potentially decreased amyotrop

48 el blockers (CCBs) or angiotensin-converting enzyme inhibitors (ACEis), respectively.

49 ptable alternative to angiotensin-converting enzyme inhibitors (ACEIs).

50 let therapy, statins, angiotensin-converting enzyme inhibitors [ACEIs] or angiotensin receptor blocke

51 medication was taken (angiotensin-converting enzyme inhibitors [ACEIs], angiotensin receptor blockers

52 al and X-ray crystallographic studies of the enzyme-inhibitor adducts helped us to rationalize the ob

53 as found for users of angiotensin-converting enzyme inhibitors (adjusted OR 1 .

54 e target protein to the ligand perturbs this enzyme-inhibitor affinity due to the generation of steri

55 Angiotensin-converting enzyme inhibitor also significantly prolonged allograft

56 Studies using an enzyme inhibitor and a range of real world possible inte

57 riate prescription of angiotensin-converting enzyme inhibitor and beta-blockers and in the composite

58 ked mice treated with angiotensin-converting enzyme inhibitors and a single bolus of icatibant (HOE-1

59 rug classes: statins, angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers,

60 Uptitration of angiotensin-converting enzyme inhibitors and beta blockers was performed over 6

61 Angiotensin-converting enzyme inhibitors and beta-blockers are recommended firs

62 We hypothesized that angiotensin-converting enzyme inhibitors and beta-blockers could prevent trastu

63 c, heart failure with angiotensin-converting enzyme inhibitors and beta-blockers in certain pediatric

64 Angiotensin-converting enzyme inhibitors and beta-blockers prevent LVSD in anim

65 e probe provides a new opportunity to screen enzyme inhibitors and evaluate the apoptosis-associated

66 mistry are showcased herein with examples of enzyme inhibitors and ligands for G protein-coupled rece

67 outs to predict the impact of both metabolic enzyme inhibitors and metabolic pathways exploited to ov

68 s with yet unknown functions, in addition to enzyme inhibitors and peptidase regulators.

69 ised to make a major impact on the design of enzyme inhibitors and receptor modulators.

70 Our aims were to identify target enzyme inhibitors and to benchmark a variety of computer

71 standard therapy with angiotensin-converting enzyme inhibitors and/or angiotensin receptor blockers a

72 lved in signaling have lower affinities than enzyme-inhibitor and antibody-antigen complexes, and the

73 e using MLN4924 (a specific Nedd8-activating enzyme inhibitor) and observed a marked increase in ENaC

74 cation (beta-blocker, angiotensin converting enzyme inhibitor, and angiotensin receptor blocker), and

75 mbotic, beta blocker, angiotensin-converting enzyme inhibitor, and statin agents minimize ongoing car

76 rgic blocking agents, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in

77 etics, beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers inc

78 nt therapy with ARBs, angiotensin-converting enzyme inhibitors, and antiarrhythmic drugs was prohibit

79 robial agents, lung surfactant replacements, enzyme inhibitors, and catalysts, among many other appli

80 ss how this information guides the design of enzyme inhibitors, and explain how the molecules were op

81 pirin, beta blockers, angiotensin-converting enzyme inhibitors, and statins) in pharmacies gathered f

82 erval, 0.64-0.98] for angiotensin-converting enzyme inhibitors; and relative risk, 0.7 [95% confidenc

83 rug treatment with an angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, calcium

84 llowing: medications (angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, bet

85 Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-b

86 /g) and taking stable angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or bot

87 classes examined were angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, alpha-

88 d background drugs of angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, beta b

89 medications including angiotensin-converting-enzyme inhibitors, angiotensin-receptor blockers, beta-b

90 of medications (i.e., angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, calciu

91 th a beta-blocker, an angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker (ACE-I/

92 ospital and discharge angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers, beta-

93 istics (shock, use of angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers, lacta

94 CI: 0.31-0.85), using angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (beta=0.36

95 ding statin, fibrate, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker and oral a

96 ess likely to receive angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy (P

97 Angiotensin-converting enzyme inhibitor/angiotensin receptor blocker uptake inc

98 in, beta-blocker, and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use in pat

99 ide, pkVO2, NYHA, and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use-is wel

100 ived at least 1 GDMT (angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, or beta-b

101 in, beta-blocker, and angiotensin-converting enzyme inhibitor/angiotensin receptor blocker.

102 rin at discharge, (3) angiotensin-converting enzyme inhibitor/angiotensin receptor blockers for systo

103 c kidney disease, and angiotensin-converting enzyme inhibitors/angiotensin II receptor blockade use r

104 tion fraction, use of angiotensin-converting enzyme inhibitors/angiotensin receptor antagonists, use

105 0.1) and reversed for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (66% ver

106 from 44% to 100% for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (median,

107 re less likely to use angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and beta

108 tes of treatment with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and beta

109 ment with statins and angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on outco

110 erval, 1.08-1.18) for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy,

111 patients on statins, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and bet

112 nce to beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and sta

113 ion of beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, and sta

114 5%, 76%, and 61% used angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-bl

115 had greater usage of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-bl

116 ents were on statins, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-bl

117 scharge with statins, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-bl

118 of patients receiving angiotensin-converting enzyme inhibitors/angiotensin receptors blockers, beta-b

119 Angiotensin-converting enzyme inhibitors are associated with deleterious hypote

120 rmacologic effects of angiotensin-converting enzyme inhibitors are partly mediated by increased brady

121 like beta-blockers or angiotensin-converting enzyme inhibitors) are considered contraindicated in cur

122 otein structure determination and to develop enzyme inhibitors as angiogenic regulators to treat meta

123 ed approaches are used routinely to discover enzyme inhibitors as cellular tools and potential therap

124 bitor deficiency, and angiotensin-converting enzyme inhibitor-associated angioedema." This is a compl

125 ramipril for 7 days (angiotensin-converting enzyme inhibitors) before hemorrhagic shock, 4) shocked

126 This effect was blocked by the enzyme inhibitor benzolamide and mimicked by the additio

127 lso been treated with angiotensin-converting enzyme inhibitors, beta-blockers, and growth hormone rep

128 filled prescriptions angiotensin-converting enzyme inhibitors, beta-blockers, and statins.

129 Enzyme-substrate and enzyme-inhibitor binding experiments were performed usin

130 elet agents, statins, angiotensin-converting enzyme inhibitors, blood pressure control, lipid control

131 f COX-2 protein, which was restored by COX-2 enzyme inhibitors but not by proteasomal and lysosomal i

132 he presence of associated protein matrix and enzyme inhibitors, but accelerated by endogenous amyloly

133 Angiotensin-converting enzyme inhibitors can delay the progression of subclinic

134 demonstrate that the coadministration of key enzyme inhibitors can effectively prolong the survival o

135 II receptor blockers, angiotensin-converting enzyme inhibitors) can modify the host response to infla

136 ining THR-123 and the angiotensin-converting enzyme inhibitor captopril had an additive therapeutic b

137 and valsartan and the angiotensin-converting enzyme inhibitor captopril on wound healing in diabetic

138 constant of the initially formed reversible enzyme-inhibitor complex (no "tight binding").

139 Reduction of the crystalline enzyme-inhibitor complex causes profound structural chan

140 pK(EHI) approximately 10 for the protonated enzyme-inhibitor complex EH*I(3-).

141 n reactivity to achieve potency, noncovalent enzyme-inhibitor complex partitioning between inhibitor

142 an the structural-alignment-based method for enzyme-inhibitor complex prediction.

143 e active site of the enzyme, resulting in an enzyme-inhibitor complex that replicates the enzyme's te

144 binding rather than the ground state of the enzyme-inhibitor complex, and demonstrates the important

145 d to the trapping of a water molecule in the enzyme-inhibitor complex, as had been observed earlier f

146 tron diffraction data from the perdeuterated enzyme-inhibitor complex, we were able to determine the

147 verned by the thermodynamic stability of the enzyme-inhibitor complex.

148 hibited by SBT3PP with a Kd of 74 nm for the enzyme-inhibitor complex.

149 ibed, along with crystal structures of their enzyme-inhibitor complexes.

150 on guided by three-dimensional structures of enzyme-inhibitor complexes.

151 strate dehydroepiandrosterone sulfate or the enzyme inhibitor COUMATE, influenced behavior in a novel

152 t categories, namely, angiotensin-converting enzyme inhibitor, cyclooxygenase inhibitor, and dopamine

153 ntly, SKI-1 inhibition by the cell-permeable enzyme inhibitor decanoyl-RRLL-chloromethylketone (dec-R

154 ly unrelated prolyl hydroxylase domain (PHD) enzyme inhibitors: dimethyloxalyl glycine and FG-4497.

155 e peptide by a specific protease also causes enzyme-inhibitor dissociation, leading to signal generat

156 for the detection of angiotensin-converting enzyme inhibitor drug, captopril, is presented.

157 slow step consisting of the formation of the enzyme-inhibitor (EI) complex.

158 00 mg daily) with the angiotensin-converting enzyme inhibitor enalapril (20 mg daily) in 8399 patient

159 F), compared with the angiotensin-converting enzyme inhibitor enalapril, and improves peripheral insu

160 luding cytokines and chemokines, enzymes and enzyme inhibitors, extracellular matrix proteins, and me

161 channel blockers and angiotensin-converting enzyme inhibitors for cardiovascular protection.

162 basis for a simple screening method for new enzyme inhibitors for disease treatment.

163 evelop novel FAS-II FabI enoyl-ACP reductase enzyme inhibitors for Francisella and other select agent

164 ors could offer an orthogonal alternative to enzyme inhibitors for perturbation of enzyme activity in

165 promising strategy for creating multivalent enzyme inhibitors for selectively imaging extracellular

166 s, beta-blockers, and angiotensin-converting enzyme inhibitors given to patients after myocardial inf

167 TACE (tumor necrosis factor-alpha-converting enzyme) inhibitor GM6001 was ineffective.

168 ssure lowering in the angiotensin-converting enzyme inhibitor group (p < 0.001).

169 ficantly lower in the angiotensin-converting enzyme inhibitor group than in the other groups (p < 0.0

170 icantly higher in the angiotensin-converting enzyme inhibitor group than in the other groups, particu

171 asodilators including angiotensin-converting enzyme inhibitors have been evaluated in clinical trials

172 Intracoronary angiotensin-converting enzyme inhibitors have been shown to relieve myocardial

173 In addition, the incorporation of enzyme inhibitors (i.e., quaternary ammonium methacrylat

174 ly before anesthesia (angiotensin-converting enzyme inhibitors + icatibant), and 5) shocked mice trea

175 novel potent and selective NEDD8-activating enzyme inhibitor in a panel of MCL cell lines, primary M

176 ocker, statin, and an angiotensin-converting enzyme inhibitor in patients with left ventricular eject

177 or was superior to an angiotensin-converting enzyme inhibitor in reducing mortality in patients with

178 eevaluate the role of angiotensin-converting enzyme inhibitors in humans with AR in a large, carefull

179 antly associated with angiotensin-converting-enzyme inhibitors in our metabolome-wide association ana

180 PPARalpha and fatty acid oxidation enzyme inhibitors increased DEX-mediated killing of CLL

181 1-INH deficiency, and angiotensin-converting enzyme inhibitor-induced angioedema does not typically p

182 ioedema type III, and angiotensin converting enzyme inhibitor-induced angioedema.

183 structures proved new information about the enzyme-inhibitor interaction and the potential therapeut

184 ional docking studies provided insights into enzyme-inhibitor interactions and a rationale for the ob

185 y of PRDelta4 is attributable to stabilizing enzyme-inhibitor interactions in the P2 and P2' pockets

186 ing to FXIIIa, in turn, the knowledge of the enzyme-inhibitor interactions might bring about comprehe

187 In order to probe the nature of the enzyme-inhibitor interactions, molecular dynamics simula

188 ulations were carried out to inspect crucial enzyme/inhibitor interactions such as hydrophobic intera

189 Enzyme inhibitors like drugs and pollutants are closely

190 The angiotensin converting enzyme inhibitor lisinopril and mineralocorticoid recept

191 Hg) and to either an angiotensin-converting-enzyme inhibitor (lisinopril) plus an angiotensin-recept

192 farnesyltransferase (FNTA) by siRNA and the enzyme inhibitor manumycin A caused elevation of ApoA-I

193 cell lineage commitment and suggest that Car enzyme inhibitors may possess therapeutic potential that

194 The Nedd8 activation enzyme inhibitor MLN4924 blocks the activity of the host

195 The NEDD8-activating enzyme inhibitor MLN4924 reportedly blocked cullin neddy

196 at includes either an angiotensin-converting enzyme inhibitor (moderate-quality evidence) or an angio

197 te that metals can be therapeutically viable enzyme inhibitors; moreover, enzymes that share homology

198 antagonists (n=6) or angiotensin-converting enzyme inhibitors (n=6) exhibited no significant differe

199 ceived beta-blockers, angiotensin-converting enzyme inhibitors, nitrates, and statins (all p < 0.05).

200 Moreover, an angiotensin-converting enzyme inhibitor normalized CXCR4 and AT1 receptor expre

201 dual inhibitors targeting both IN and other enzymes, inhibitors of enzymes that activate IN, activat

202 e effect of 2-chloroacetamidine (2CA), a PAD enzyme inhibitor, on OVA-immunized and airway-challenged

203 e currently taking an angiotensin-converting enzyme inhibitor or an angiotensin II-receptor blocker.

204 e pathway, such as an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker, sho

205 of patients not on an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker were

206 nephropathy receiving angiotensin converting enzyme inhibitor or angiotensin receptor blocker backgro

207 ta-blocker and either angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in elig

208 nsive therapy with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in pers

209 atients (84%) used an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker through

210 renal function, lower angiotensin-converting enzyme inhibitor or angiotensin receptor blocker usage d

211 e classification, and angiotensin converting enzyme inhibitor or angiotensin receptor blocker usage w

212 <90 mm Hg diastolic), angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use, an

213 ification, and use of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker.

214 ears, with subsequent angiotensin-converting enzyme inhibitor or beta-blocker treatment for patients

215 mice treated with an angiotensin-converting enzyme inhibitor or lacking angiotensinogen.

216 less likely to be on angiotensin-converting enzyme inhibitors or aldosterone antagonists.

217 12.23]; P=0.009), and angiotensin-converting enzyme inhibitors or angiotensin II receptor blockade us

218 eta-blockers (82.5%), angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (8

219 s with intolerance to angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers.

220 wed by treatment with angiotensin-converting enzyme inhibitors or angiotensin II-receptor blockers.

221 ose only treated with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (18.2

222 0.030) and trends for angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (HR,

223 ge were not receiving angiotensin-converting enzyme inhibitors or angiotensin receptor blockers at ad

224 n contrast, the use of angiotensin-convering enzyme inhibitors or angiotensin receptor blockers durin

225 lockers, statins, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for s

226 of HF, initiation of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers was i

227 >1 g/d, maintained on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers with

228 atins, beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and

229 beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and

230 -dependent effects of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, anti

231 contraindications for angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, beta

232 ystem with the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

233 beta-blockers and 81% angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

234 edications other than angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

235 , and 84% were taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

236 ibitors, statins, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.

237 blockade therapy with angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers after

238 s who were prescribed angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers after

239 ropriate medications (angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers and s

240 ropriate medications (angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers and s

241 nts were treated with angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers.

242 kely to be prescribed angiotensin-converting enzyme inhibitors or beta-blockers.

243 ibition by enalapril (angiotensin-converting enzyme inhibitor) or losartan (angiotensin-receptor bloc

244 enzyme is completely inhibited at 1:4 ratio (enzyme:inhibitor) or greater, a number that agrees with

245 atins, beta-blockers, angiotensin-converting enzyme inhibitors, or angiotensin receptor blockers.

246 clude a beta-blocker, angiotensin-converting enzyme inhibitor, oral antidiabetic agent, calcium, and

247 seline beta-blockers, angiotensin-converting enzyme inhibitors, oral anticoagulants, and implantable

248 vered for statins and angiotensin-converting enzyme inhibitors, patients were stratified as fully adh

249 stration of the M13-metalloproteinase family enzyme-inhibitor phosphoramidon, using the senescence-ac

250 mice pretreated with angiotensin-converting enzyme inhibitors potentiated IFN-gamma production by Ag

251 Further, angiotensin-converting enzyme inhibitors potentiated TCT-evoked paw edema in BA

252 eceptor blockers, and angiotensin-converting enzyme inhibitors; prophylactic surgery for aneurysm; su

253 proach for the extensive characterization of enzyme-inhibitor reaction kinetics within a single exper

254 first to show that endocannabinoid catabolic enzyme inhibitors reduce abrupt withdrawal in morpine-de

255 ensin II (Ang II) and angiotensin converting enzyme inhibitors regulated blood EPO levels.

256 on beta-blockers and angiotensin-converting enzyme inhibitors, respectively.

257 Angiotensin-converting enzyme inhibitor significantly decreased nanoparticle si

258 gents, beta-blockers, angiotensin-converting enzyme inhibitor, statins at discharge, and the composit

259 ovide a foundation upon which to develop new enzyme inhibitors targeting the hijacking of N-glycan sy

260 proof of concept, we tested the effect of an enzyme inhibitor (targeting matrix metalloproteinase 12)

261 It is an angiotensin-converting enzyme inhibitor that operates via chelating copper at t

262 intained to mitigate effects of biosynthetic enzyme inhibitors that substantially change the proporti

263 ibiotic) and pacritinib (an 18-membered-ring enzyme inhibitor), the Z-isomer of which is less potent

264 For example, in the case of enzyme inhibitors, the interactions of the metallacarbor

265 necrosis, and use of angiotensin-converting enzyme inhibitor therapy for microalbuminuria in adults

266 nts with COPD in whom angiotensin-converting enzyme inhibitor therapy improves renal and lung functio

267 tril-valsartan versus angiotensin-converting enzyme inhibitor therapy in patients with chronic heart

268 omodulatory impact of angiotensin-converting enzyme inhibitor therapy on myeloid cells in allografts.

269 clinical benefit from angiotensin-converting enzyme inhibitor therapy regardless of renal function.

270 ention of Events With Angiotensin-Converting Enzyme Inhibitor Therapy) trial.

271 clinical benefit from angiotensin-converting enzyme inhibitor therapy.

272 nificant benefit from angiotensin-converting enzyme inhibitor therapy.

273 sin Inhibitor With an Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality

274 inhibitor) with ACEI (angiotensin-converting enzyme inhibitor) to Determine Impact on Global Mortalit

275 Inhibitor] with ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Impact on Global Mortalit

276 Inhibitor] With ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Impact on Global Mortalit

277 Inhibitor] with ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Impact on Global Mortalit

278 hemorrhagic shock in angiotensin-converting enzyme inhibitor-treated mice.

279 uld be of interest in angiotensin-converting enzyme inhibitor-treated patients during both emergency

280 hemodynamic effect of angiotensin-converting enzyme inhibitor treatment in mice.

281 the possibility that angiotensin-converting enzyme inhibitor treatment might limit PEC activation an

282 ospective analysis of angiotensin-converting enzyme inhibitor trials and prospective comparisons with

283 We show that the histone deacetylase (HDAC) enzyme inhibitor trichostatin A blocks the ability of li

284 n II receptor blocker/angiotensin-converting enzyme inhibitor use were associated with reduced early

285 m channel blocker and angiotensin-converting enzyme inhibitor use.

286 agents, aspirin, and angiotensin-converting enzyme inhibitors was identified.

287 il/valsartan, over an angiotensin-converting enzyme inhibitor, was consistent regardless of backgroun

288 ry high sensitivity for the detection of the enzyme inhibitor, which is around 1 fM.

289 scribed chaperones of glucocerebrosidase are enzyme inhibitors, which complicates their clinical deve

290 xtures containing bioactive compounds (i.e., enzyme inhibitors), while the second step uses bioselect

291 sponse and the development of anti-CoV PLpro enzyme inhibitors will be a challenging undertaking.

292 ified as a potent and highly selective PDE2a enzyme inhibitor with favorable rat pharmacokinetic prop

293 lly bioavailable and brain penetrating PDE1B enzyme inhibitor with potent memory-enhancing effects in

294 o the discovery of compound 3, an equipotent enzyme inhibitor with significant improvements in passiv

295 easible to rapidly and reliably identify Nox enzyme inhibitors with a markedly lower rate of false po

296 ls that have compared angiotensin-converting enzyme inhibitors with drugs that inhibit both the renin

297 ization of the series yielding submicromolar enzyme inhibitors with promising cellular activity.

298 ign of unique allosteric sites for potential enzyme inhibitors with regulatory or therapeutic benefit

299 a, and 10b showed increased potency as PDE4D enzyme inhibitors with respect to 2 and a good selectivi

300 hat the in vivo coadministration of specific enzyme inhibitors would improve peptide bioavailability